Cadrenal Therapeutics launches partnering process for late-stage cardiac critical care assets

Cadrenal Therapeutics, Inc.

Portfolio aligned into three pillars: Pre-Operative Safety (frunexian), Orphan Regulatory Acceleration (tecarfarin), Post-Operative Shield (CAD-1005).
Phase 2 CAD-1005 data showed >25% absolute reduction in thrombotic events in heparin-induced thrombocytopenia patients.
Seeking out-licensing, portfolio monetization, or commercial co-development partnerships for late-stage assets.
Also advancing oral 12-LOX inhibitor CAD-2000 for chronic cardiorenal inflammatory and thrombotic indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.